Extracellular vesicle-mediated gene therapy targets BRAF^V600E-mutant colorectal cancer by inhibiting the MEK1/2-ERK1/2 pathway.

ABSTRACT:

Background

Patients with colorectal cancer (CRC) harboring BRAF mutation have a poor prognosis. The median survival time for patients with advanced BRAF^V600E-mutant CRC is only approximately one year. Owing to the insensitivity to standard chemotherapy, there are still no effective and highly specific treatment strategies available in clinical practice for CRC patients with BRAF mutation. Therefore, targeting the BRAF^V600E mutation site, researching and exploring novel targeted therapies are essential to improve the survival rate of patients with this CRC subtype.

Aim

This study aims to develop a precise therapeutic system for BRAF^V600E CRC, based on the carrier properties of extracellular vesicles (EVs) and gene therapy targeting BRAF^V6

SUBMITTER: Wang D 

PROVIDER: S-EPMC11843959 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature